Guardant Health, Inc. - Common Stock (GH)

145.83
+0.24 (0.16%)
NASDAQ · Last Trade: Nov 22nd, 5:57 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close145.59
Open143.10
Bid146.55
Ask151.00
Day's Range141.00 - 148.27
52 Week Range74.55 - 191.05
Volume2,757,603
Market Cap14.77B
PE Ratio (TTM)-39.63
EPS (TTM)-3.7
Dividend & YieldN/A (N/A)
1 Month Average Volume2,289,727

Chart

About Guardant Health, Inc. - Common Stock (GH)

Guardant Health is a biotechnology company that specializes in developing advanced genomic tests for cancer patients. The company focuses on providing innovative liquid biopsy solutions, which involve analyzing circulating tumor DNA from blood samples to help detect and monitor cancers more effectively. Their tests are designed to aid physicians in making informed treatment decisions, enabling personalized medicine approaches that can improve patient outcomes. Through their cutting-edge technology and extensive research, Guardant Health aims to transform cancer care by delivering actionable insights and facilitating early detection and ongoing management of the disease. Read More

News & Press Releases

Guardant Health Sees Shield Coverage Boost in 2027, Holds Cash Flow Break-Even Targetmarketbeat.com
Guardant Health (NASDAQ:GH) expects expanded insurance coverage for its Shield screening test and continued growth in its cancer testing portfolio to support its business in 2027, while maintaining a target of reaching free cash flow break-even in the fourth quarter of that year. Speaking at a comp
Via MarketBeat · November 22, 2026
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates
By FN Media · Via GlobeNewswire · November 20, 2026
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:GH),(NASDAQ:GRAL),(NASDAQ:NTRA),(NASDAQ:FRNM) EQNX::TICKER_END
Via FinancialNewsMedia · November 20, 2026
Guardant Health Inc (NASDAQ:GH) Falls 12% Despite In-Line Q3 Revenue as Guidance Disappointschartmill.com
Via Chartmill · November 5, 2026
Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant’s Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific genomic alterations to provide one of the most advanced and actionable views of MRD.
By Guardant Health, Inc. · Via Business Wire · November 19, 2026
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
By Guardant Health, Inc. · Via Business Wire · November 13, 2026
Guardant Health Prices $500 Million Convertible Senior Notes Offering
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on November 16, 2026, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes.
By Guardant Health, Inc. · Via Business Wire · November 12, 2026
Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
By Guardant Health, Inc. · Via Business Wire · November 11, 2026
Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient’s cancer may respond to treatment in the absence of traditional biomarkers.
By Guardant Health, Inc. · Via Business Wire · November 11, 2026
PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorectal cancer metastases.
By Guardant Health, Inc. · Via Business Wire · November 10, 2026
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
By Guardant Health, Inc. · Via Business Wire · November 9, 2026
Guardant Health (GH) Q3 2026 Earnings Call Transcriptfool.com
Shield cost per test beat its target early while screening guidance moved higher.
Via The Motley Fool · November 6, 2026
GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability
Diagnostics company Guardant Health (NASDAQ:GH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 36.1% year on year to $36...
Via StockStory · November 6, 2026
1 healthcare stock to research further and 2 we avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via StockStory · November 5, 2026
What Guardant Health (GH) Said on Its Q3 Earnings Callmarketbeat.com
Guardant Health (NASDAQ:GH) raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test. The company reported revenue of $361 million for the quarter ended Sept. 30,
Via MarketBeat · November 5, 2026
Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 36.1% year on year to $361 million. The c...
Via StockStory · November 5, 2026
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.
By Guardant Health, Inc. · Via Business Wire · November 5, 2026
Guardant Health earnings: what to look for from GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings this Thursday after the bell. Here’s what to expect. Guardant Health beat analysts...
Via StockStory · November 3, 2026
Kevin Sayer Joins Guardant Health Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology.
By Guardant Health, Inc. · Via Business Wire · November 3, 2026
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increasing screening participation for CRC.
By Guardant Health, Inc. · Via Business Wire · November 3, 2026
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 million Pennsylvanians of screening-eligible age.1
By Guardant Health, Inc. · Via Business Wire · October 29, 2026
3 Reasons GH is risky and 1 stock to buy instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu...
Via StockStory · October 26, 2026
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
By Guardant Health, Inc. · Via Business Wire · October 20, 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winningmarketbeat.com
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via MarketBeat · October 19, 2026
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee.
By Guardant Health, Inc. · Via Business Wire · October 15, 2026